諾唯贊(688105.SH):諾唯贊醫療與上藥醫療簽訂約2.15億元經銷合同
格隆匯3月16日丨諾唯贊(688105.SH)公佈,公司全資子公司南京諾唯贊醫療科技有限公司(簡稱“諾唯贊醫療”、“甲方”)近日與上藥醫療器械(上海)有限公司(簡稱“上藥醫療”、“乙方”)簽訂了《經銷合同》。
根據合同約定,諾唯贊醫療授權上藥醫療在上海市、其100%股東上藥控股有限公司及其下屬子公司在公共衞生專業醫用物資採購項目上為諾唯贊醫療授權經銷商;上藥醫療計劃向諾唯贊醫療採購合計人民幣2.15億元(含税)的新型冠狀病毒抗原檢測試劑盒。上述採購金額超過公司最近一個會計年度經審計營業成本的50%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.